IDT Australia Ltd
ASX:IDT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
IDT Australia Ltd
Income from Continuing Operations
IDT Australia Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IDT Australia Ltd
ASX:IDT
|
Income from Continuing Operations
-AU$6.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Income from Continuing Operations
-AU$30.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Income from Continuing Operations
-AU$90.1m
|
CAGR 3-Years
26%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Income from Continuing Operations
AU$30.4m
|
CAGR 3-Years
449%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Income from Continuing Operations
-AU$64.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Income from Continuing Operations
AU$10.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
IDT Australia Ltd
Glance View
IDT Australia Ltd. produces, develops and supplies pharmaceutical products. The company is headquartered in Melbourne, Victoria. The firm is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. The firm specializes in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging and pharmacy services. The company provides services for new drug development and scale-up, commercial active drug manufacture as well as a various oral and injectable finished drug dose forms. Its sterile manufacturing suite is designed to liquid fill and lyophilise a range of sterile pharmaceutical and biopharmaceutical drug products. Its current goods manufacturing practices (cGMP) facilities manufactures a range of medicinal cannabis products for local and international markets.
See Also
What is IDT Australia Ltd's Income from Continuing Operations?
Income from Continuing Operations
-6.1m
AUD
Based on the financial report for Dec 31, 2025, IDT Australia Ltd's Income from Continuing Operations amounts to -6.1m AUD.
What is IDT Australia Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-7%
Over the last year, the Income from Continuing Operations growth was -28%. The average annual Income from Continuing Operations growth rates for IDT Australia Ltd have been 9% over the past three years , and -7% over the past ten years .
